LHFPL4 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09574
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of Human LHFPL4 (NP_940962). Peptide sequence LCLVLGCMIFPDGWDAETIRDMCGAKTGKYSLGDCSVRWAYILAIIGILN
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
27 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for LHFPL4 Antibody
Western Blot: LHFPL4 Antibody [NBP3-09574]
Western Blot: LHFPL4 Antibody [NBP3-09574] - Western blot analysis of LHFPL4 in Fetal Heart lysates. Antibody dilution at 1.0ug/mlApplications for LHFPL4 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: LHFPL4
Alternate Names
LHFP-like protein 4, lipoma HMGIC fusion partner-like 4, lipoma HMGIC fusion partner-like 4 protein, MGC133162
Gene Symbol
LHFPL4
Additional LHFPL4 Products
Product Specific Notices for LHFPL4 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...